- Conditions
- Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Interventions
- sargramostim, quality-of-life assessment, radiation therapy
- Biological · Procedure · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 217
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 167 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1201–1224
of 5,275
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cystic Fibrosis
- Interventions
- tgAAVCF
- Genetic
- Lead sponsor
- Targeted Genetics Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Diego, California + 7 more
- Conditions
- Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia
- Interventions
- Ciprofloxacin 750 MG, Etoposide, Ciprofloxacin 1000 MG, Ciprofloxacin 500 mg
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Thrombosis
- Interventions
- Rivaroxaban, Acetylsalicylic Acid
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 8 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Gainesville, Florida • Oak Lawn, Illinois + 14 more
- Conditions
- Endocrine, Nutritional, Metabolic and Immunity Disorders
- Interventions
- 50 grams of whole wheat bran cereal, 100 grams of whole wheat bran cereal
- Dietary Supplement
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack
- Interventions
- Dexpramipexole Dihydrochloride, Placebo
- Drug
- Lead sponsor
- Areteia Therapeutics
- Industry
- Eligibility
- 12 Years to 99 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 146
- States / cities
- Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 123 more
- Conditions
- Healthy
- Interventions
- 35 mg risedronate DR tablet
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 40 Years to 70 Years · Female only
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 4
- States / cities
- Gainesville, Florida • Miami, Florida • Honolulu, Hawaii + 1 more
- Conditions
- Cervical Cancer, Endometrial Cancer, Gastrointestinal Complications, Perioperative/Postoperative Complications, Radiation Toxicity, Urinary Complications, Urinary Tract Toxicity
- Interventions
- Standard radiation therapy, intensity-modulated radiation therapy
- Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 129
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 106 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- irinotecan, Carboplatin, sunitinib
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 10
- States / cities
- Fort Myers, Florida • Orlando, Florida • Gainesville, Georgia + 7 more
- Conditions
- Breast Cancer
- Interventions
- educational intervention, therapeutic dietary intervention
- Other · Procedure
- Lead sponsor
- Institute for Cancer Prevention (IFCP)
- Other
- Eligibility
- 48 Years to 78 Years · Female only
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2006
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 32 more
- Conditions
- Sepsis
- Interventions
- Isomark Canary™
- Device
- Lead sponsor
- Isomark, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 6
- States / cities
- Gainesville, Florida • Jacksonville, Florida • St Louis, Missouri + 2 more
- Conditions
- Adult Hematopoietic Cell Transplant (HCT) Survivors 1-2 Yrs Post Most Recent HCT
- Interventions
- Individualized Survivorship Care Plan (SCP)
- Other
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 495 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Gainesville, Florida • Maywood, Illinois + 13 more
- Conditions
- Hematologic Malignancy
- Interventions
- Age 60+ with planned HCT for Hematologic Malignancy
- Diagnostic Test
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 60 Years and older
- Enrollment
- 1,229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Duarte, California • San Francisco, California + 41 more
- Conditions
- Healthy Adult Participants
- Interventions
- Alcohol (Oral), Placebo Control
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 65 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Heart Failure, Congestive
- Interventions
- Levosimendan
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 132
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 97 more
- Conditions
- Obesity, Overweight
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 15,374 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 165
- States / cities
- Gilbert, Arizona • Mesa, Arizona • Phoenix, Arizona + 141 more
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
- Interventions
- Brentuximab Vedotin, Crizotinib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 154
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 117 more
- Conditions
- Constipation - Functional
- Interventions
- Lubiprostone
- Drug
- Lead sponsor
- Sucampo Pharma Americas, LLC
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 419 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 67
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 60 more
- Conditions
- Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
- Interventions
- Sodium Fusidate, Placebo
- Drug
- Lead sponsor
- Aceragen
- Industry
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 25
- States / cities
- Gainesville, Florida • Orlando, Florida • Pensacola, Florida + 22 more
- Conditions
- Lupus Nephritis, Primary Membranous Nephropathy
- Interventions
- NKX019, Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- Nkarta, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 17
- States / cities
- Little Rock, Arkansas • Tustin, California • Gainesville, Florida + 14 more
- Conditions
- Bacterial Pneumonia
- Interventions
- IV meropenem, I.V. Meropenem, Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h, Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage., tobramycin nebulization
- Drug · Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 8
- States / cities
- San Mateo, California • Gainesville, Florida • Atlanta, Georgia + 5 more
- Conditions
- Lewy Body Dementia
- Interventions
- LY3154207, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
- Conditions
- Hypertension
- Interventions
- Metoprolol, Chlorthalidone
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 839 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • Atlanta, Georgia • Rochester, Minnesota
- Conditions
- Unruptured Wide-neck Aneurysms
- Interventions
- Citadel Embolization Device
- Device
- Lead sponsor
- Stryker Neurovascular
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 25
- States / cities
- Los Angeles, California • San Francisco, California • Walnut Creek, California + 18 more